Sign in
Taking people in SpainPhase 2

Adding bevacizumab to encorafenib and cetuximab for BRAF V600E colorectal cancer

Tests encorafenib, cetuximab and bevacizumab in BRAF V600E colorectal cancer.

Key facts

Who runs it
Vall D Hebron Institute Of Oncology
Where
A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo, Santander, Valencia, and Zaragoza, SpainSee the 15 sites
Registry title
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
Status
Recruiting
Phase
Phase 2
People taking part
94 people, planned
Started
17 May 2024
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
19 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic colorectal cancer that has a BRAF V600E mutation and has grown after 1 or 2 earlier treatment regimens.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Metastatic colorectal cancer, confirmed by tissue or cell tests. The disease has progressed after 1 or 2 earlier regimens in the metastatic setting.
Earlier treatment
Must have had 1 or 2 earlier treatment regimens for metastatic disease, with the disease progressing afterwards.
Biomarker or test result
BRAF V600E mutation in tumor tissue. Must be able to receive cetuximab according to the local label, based on tumor RAS status.

Main reasons for not taking part

  • Significant vascular disease in the 6 months before cycle 1, day 1
  • Bleeding disorder or clinically significant coagulopathy
  • Tumors with microsatellite instability or mismatch repair deficiency
  • Stomach or bowel problems that may change how encorafenib is absorbed
  • Blood clot or stroke-type event in the 6 months before starting treatment

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Histologically- or cytologically-confirmed mCRC that is metastatic
  • Presence of BRAF V600E mutation in tumor tissue previously determined according to the guidelines of each center, any time point before the enrollment in the study
  • Eligible to receive cetuximab per locally approved label with regard to tumor RAS status, any time point before the enrollment in the study
  • Progression of disease after 1 or 2 prior regimens in the metastatic setting

Who cannot take part

  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1
  • History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary embolism
  • Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
  • Impaired gastrointestinal (GI) function or disease that may significantly alter the absorption of encorafenib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
  • Concurrent or previous other malignancy within 5 years of study entry without Sponsor approval, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
  • Tumors with microsatellite instability or mismatch repair deficiency

Where in Spain

  • Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
  • Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
  • Hospital del MarBarcelona, SpainTaking people
  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Hospital Universitario Reina SofiaCórdoba, SpainTaking people
  • Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
  • Hospital Clínico San CarlosMadrid, SpainTaking people
  • Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people
  • Hospital Universitario Regional de MálagaMálaga, SpainTaking people
  • Hospital Universitario Central De AsturiasOviedo, SpainTaking people
  • Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
  • Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
  • Hospital General Universitario de ValenciaValencia, SpainTaking people
  • Hospital Unviersitario Miguel ServetZaragoza, SpainTaking people

About the trial

What the trial wants to find out

To evaluate the antitumor activity of the combination of encorafenib, cetuximab and bevacizumab in subjects who have progressed to one or two chemotherapeutic regimens for BRAF V600E-mutant mCRC. For the safety lead-in phase only: To assess the safety and tolerability of the combination of encorafenib, cetuximab and bevacizumab.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial
Plain-language title
Adding bevacizumab to encorafenib and cetuximab for BRAF V600E colorectal cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
19 June 2026